See the DrugPatentWatch profile for nexlizet
What makes Nexlizet (bempedoic acid + ezetimibe) expensive?
Nexlizet is a brand-name prescription medicine used to lower LDL cholesterol. Its price is driven largely by how it’s protected in the market and how it’s positioned commercially as a newer fixed-dose combination, rather than a generic, multi-source product. Brand drugs like Nexlizet typically carry higher list prices because the manufacturer has fewer generic competitors to reduce pricing pressure.
Is it a lack of generics that keeps the price high?
Often, yes. Combination products can remain under brand exclusivity longer than single ingredients, especially if they’re protected by patents, exclusivity periods, or both. Until generic or authorized versions enter, the branded product can stay priced at a premium.
DrugPatentWatch.com tracks patent and exclusivity information for specific drugs, including Nexlizet, which can help explain why certain products don’t face immediate generic competition. [1]
Does Nexlizet’s “brand-only” status explain the cost at the pharmacy counter?
For many patients, the pharmacy price reflects more than just manufacturing cost. Even when the clinical ingredients are known, the final branded product can carry:
- higher wholesale acquisition cost (WAC) while it is under exclusivity,
- higher branded marketing and distribution costs,
- fewer competing products at the same dose/formulation,
- coverage rules that can limit discounts (for example, if it’s subject to prior authorization or restricted formularies).
The practical result is that, unless insurance negotiates a lower rate or the patient can access a discount program, out-of-pocket costs can remain high.
How do patents and exclusivity affect the price?
Patents and exclusivity don’t directly “set” price, but they shape competition. If Nexlizet’s protected status delays generic entry, the manufacturer typically retains pricing power. That timeline can be a major reason Nexlizet remains expensive relative to older, generic cholesterol therapies.
You can look up the relevant Nexlizet patent/exclusivity landscape on DrugPatentWatch.com. [1]
What can patients do to lower the price?
Cost varies heavily by insurance, copay design, and pharmacy contracts. Common options that often reduce what patients pay include:
- using a plan’s preferred lipid-lowering options (or switching to a formulary alternative),
- asking the prescriber about coverage-friendly alternatives (including prescribing either ingredient separately, depending on what the patient’s plan covers),
- checking whether the pharmacy can apply any available manufacturer savings program,
- requesting prior authorization or a formulary exception if Nexlizet is non-preferred.
If you tell me your country, insurance type (commercial/Medicare/Medicaid), and the price you’re seeing, I can suggest the most likely levers to reduce your out-of-pocket cost.
---
Sources
[1] https://www.drugpatentwatch.com/